At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 51 enrolled
Drug / intervention
Olaratumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
In Brief
A Phase 1 clinical trial evaluating Olaratumab, Doxorubicin, and 1 other intervention for Soft Tissue Sarcoma. Completed, enrolled 51 participants across 14 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcoma
CountriesFrance, Italy, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartOct 2016
Primary CompletionJul 2018
TodayJul 2026
First PostedMay 26, 2016
Enrollment StartOct 11, 2016
Primary CompletionJul 5, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.1 years ago
Interventions
Olaratumabdrug
Administered IV
Doxorubicindrug
Administered IV
External Beam Radiotherapyradiation